Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Calderasib on Midazolam and Digoxin Pharmacokinetics
NCT06575933Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of calderasib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to Infinity of Midazolam at 24 hours, Area Under the Concentration-Time Curve from Time 0 to Last of Midazolam at 24 hours and 14 more. Started Sep 2024; status: completed.
02
Drugs
calderasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06575933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06575933.